AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12419087 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol 50 microg
Number of subjects: 21
Study 10102258 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT) for 4 months, 5 days/week, 40 minutes/session
Number of subjects: 79
Study 10102258 — intervention group
Group type: COMPARATOR
Intervention: No Physical Training (no PT)
Number of subjects: 79
Study 7768364 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (20 mg/kg body wt) daily for 3 months
Number of subjects: 60
Study 7768364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2138436 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 40 mg once daily
Number of subjects: 107
Study 2138436 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine 1 mg twice daily
Number of subjects: 107
Study 2138436 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 6643055 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthralin therapy
Number of subjects: 10
Study 6643055 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy with anthralin and steroid
Number of subjects: 10
Study 31778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported NFOD history
Number of subjects: 1307
Study 31778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically-verified NFOD history
Number of subjects: 1307
Study 31778949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both self-reported and medically-verified NFOD history
Number of subjects: 1307
Study 31778949 — intervention group
Group type: COMPARATOR
Intervention: No NFOD history
Number of subjects: 1307
Study 31655788 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically diverse intervention including peer counselor and professional support
Number of subjects: 39
Study 31655788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 39
Study 27997064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 126
Study 27997064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 26402009 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Number of subjects: 39
Study 26402009 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy for Cognitively Impaired Older Adults (ST‐CI)
Number of subjects: 39
Study 24395676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 24395676 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 22313135 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH) alone
Number of subjects: 0
Study 22313135 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) plus recombinant LH (rLH)
Number of subjects: 0
Study 19444703 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (6 weeks)
Number of subjects: 18
Study 19444703 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (6 weeks)
Number of subjects: 18
Study 21054770 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (n=140; 60%-79% maximum heart rate, 45 to 60 minutes for 8 weeks)
Number of subjects: 357
Study 21054770 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training (n=112; 60%-79% maximum heart rate, 45 to 60 minutes for 8 weeks)
Number of subjects: 357
Study 21054770 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=105; sedentary)
Number of subjects: 357
Study 16178191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion present (136 patients)
Number of subjects: 251
Study 16178191 — intervention group
Group type: COMPARATOR
Intervention: No adhesion (87 patients)
Number of subjects: 251
Study 12047962 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab every 8 weeks (group II)
Number of subjects: 573
Study 12047962 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg infliximab every 8 weeks (group III)
Number of subjects: 573
Study 12047962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group I)
Number of subjects: 573
Study 12047962 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab (group II and III combined)
Number of subjects: 573
Study 12047962 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg infliximab (group II and III)
Number of subjects: 573
Study 12047962 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg infliximab (group I)
Number of subjects: 573
Study 9565821 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg beta-carotene/kg BW/d up to 50 kg BW, 50 mg beta-carotene/d for 12 weeks, then 10 mg beta-carotene/d for 12 weeks
Number of subjects: 24
Study 9565821 — intervention group
Group type: COMPARATOR
Intervention: Placebo with starch
Number of subjects: 24
Study 7943836 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.15 minimum alveolar concentration)
Number of subjects: 14
Study 7943836 — intervention group
Group type: COMPARATOR
Intervention: Control (no halothane)
Number of subjects: 14
Study 3369709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus kallikrein (600 units per day for 3 months)
Number of subjects: 120
Study 3369709 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 120
Study 3369709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus kallikrein
Number of subjects: 120
Study 12540081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bledsoe Diabetic Conformer Boot
Number of subjects: 18
Study 12540081 — intervention group
Group type: COMPARATOR
Intervention: Fiberglass total contact cast
Number of subjects: 18
Study 30860412 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-foot exercises group
Number of subjects: 41
Study 30860412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 29986935 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (thrombectomy)
Number of subjects: 92
Study 29986935 — intervention group
Group type: EXPERIMENTAL
Intervention: TICI 2B-3 reperfusion
Number of subjects: 92
Study 29986935 — intervention group
Group type: EXPERIMENTAL
Intervention: TICI scores
Number of subjects: 92
Study 29986935 — intervention group
Group type: EXPERIMENTAL
Intervention: TICI 3 patients
Number of subjects: 92
Study 27117004 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (50 g in 300 ml of water)
Number of subjects: 20
Study 27117004 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol (75 g in 300 ml of water)
Number of subjects: 20
Study 27117004 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (75 g in 300 ml of water)
Number of subjects: 20
Study 27117004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 20
Study 24979518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2-2.5%) in Group 1
Number of subjects: 60
Study 24979518 — intervention group
Group type: COMPARATOR
Intervention: TIVA in Group 3
Number of subjects: 60
Study 24979518 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (2-2.5%) in Group 2
Number of subjects: 60
Study 21300447 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy (AR)
Number of subjects: 345
Study 21300447 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy plus Carbogen and Nicotinamide (ARCON)
Number of subjects: 345
Study 19865105 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine treatment
Number of subjects: 16
Study 19865105 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 16
Study 19597407 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia with remifentanil (group B)
Number of subjects: 100
Study 19597407 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group A)
Number of subjects: 100
Study 15955756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile stroke team intervention
Number of subjects: 308
Study 15955756 — intervention group
Group type: COMPARATOR
Intervention: Control group (general ward-based care)
Number of subjects: 308
Study 12709856 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninstrumented posterolateral fusion (PLF)
Number of subjects: 211
Study 12709856 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral fusion (VSP)
Number of subjects: 211
Study 12709856 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 fusion (interbody fusion with solid autogenous bone grafts)
Number of subjects: 211
Study 12709856 — intervention group
Group type: COMPARATOR
Intervention: Comparison of '360' with PLF
Number of subjects: 211
Study 12709856 — intervention group
Group type: COMPARATOR
Intervention: Comparison of '360' with VSP
Number of subjects: 211
Study 12709856 — intervention group
Group type: COMPARATOR
Intervention: Comparison of instrumentation (VSP and 360) with non-instrumented fusion (PLF)
Number of subjects: 211
Study 10472224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) inflated to 7 cm H2O (group II)
Number of subjects: 60
Study 10472224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) inflated to 15 cm H2O (group III)
Number of subjects: 60
Study 10472224 — intervention group
Group type: COMPARATOR
Intervention: Face mask (group I)
Number of subjects: 60
Study 10472224 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 60
Study 8608288 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus support from breast care nurse
Number of subjects: 272
Study 8608288 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 272
Study 8608288 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus support from voluntary organisation
Number of subjects: 272
Study 8608288 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus support from nurse and organisation
Number of subjects: 272
Study 1912128 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (75 mg per os)
Number of subjects: 13
Study 1912128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6429405 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 0
Study 30924714 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (13 training modules)
Number of subjects: 156
Study 30924714 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 156
Study 31388185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoural CD8+ density
Number of subjects: 1804
Study 31388185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour CD8A expression
Number of subjects: 1804
Study 30328470 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical rehabilitation with respiratory rehabilitation
Number of subjects: 63
Study 30328470 — intervention group
Group type: COMPARATOR
Intervention: Typical rehabilitation
Number of subjects: 63
Study 26611782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole 500 mg twice daily for 7 days
Number of subjects: 1365
Study 26611782 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 1365
Study 24499136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 0
Study 24499136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22589500 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care provided by memory clinic
Number of subjects: 175
Study 22589500 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by general practitioner
Number of subjects: 175
Study 20709302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of calcium, skim milk, and dairy products
Number of subjects: 125
Study 20709302 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional cup of skim milk consumed per day
Number of subjects: 125
Study 20709302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary pattern of high dairy and low fat intake
Number of subjects: 125
Study 20709302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of skim milk, dairy foods, calcium, animal protein, and potassium
Number of subjects: 125
Study 20709302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of calcium, vitamin D, skim milk, dairy foods, potassium, and a dietary pattern of high dairy and low fat
Number of subjects: 125
Study 17547799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher stents (sirolimus-eluting)
Number of subjects: 3345
Study 17547799 — intervention group
Group type: COMPARATOR
Intervention: TAXUS stents (paclitaxel-eluting)
Number of subjects: 3345
Study 17547799 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DES thrombosis
Number of subjects: 3345
Study 17547799 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall causes of thrombosis
Number of subjects: 3345
Study 16362147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily (n=11)
Number of subjects: 22
Study 16362147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 22
Study 16362147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly (open-label phase)
Number of subjects: 22
Study 16362147 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Alendronate 70 mg once weekly (open-label phase)
Number of subjects: 22
Study 11822111 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based DHE lesson plus two small group sessions
Number of subjects: 449
Study 11822111 — intervention group
Group type: COMPARATOR
Intervention: Single classroom-based DHE lesson
Number of subjects: 449
Study 9726393 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 3 weeks
Number of subjects: 227
Study 9726393 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily for 6 weeks
Number of subjects: 227
Study 9726393 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 3 weeks
Number of subjects: 227
Study 9726393 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily for 6 weeks
Number of subjects: 227
Study 7506225 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of recombinant interferon-alpha 2b three times a week for 12 weeks
Number of subjects: 45
Study 7506225 — intervention group
Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 45
Study 2662741 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30 U
Number of subjects: 100
Study 2662741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31913826 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house developed natural rubber CPR manikin
Number of subjects: 40
Study 31913826 — intervention group
Group type: COMPARATOR
Intervention: Commercial manikin
Number of subjects: 40
Study 26360825 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT meal containing 5.82 mg total capsaicinoids
Number of subjects: 0
Study 26360825 — intervention group
Group type: COMPARATOR
Intervention: CON meal with no chilli
Number of subjects: 0
Study 25751199 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-size diaphragm with acid-buffering gel
Number of subjects: 450
Study 25751199 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-size diaphragm with nonoxynol-9
Number of subjects: 450
Study 25751199 — intervention group
Group type: COMPARATOR
Intervention: Standard diaphragm (historical control)
Number of subjects: 450
Study 25751199 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-size diaphragm
Number of subjects: 450
Study 23524437 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of melatonin (1% orabase cream formula) once daily for 20 days
Number of subjects: 30
Study 23524437 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of melatonin
Number of subjects: 30
Study 23524437 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 30
Study 20878389 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 272
Study 20878389 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 272
Study 19154509 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 50
Study 17182805 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate consumption of olive oil (25 mL/d)
Number of subjects: 160
Study 17182805 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil intervention
Number of subjects: 160
Study 15527429 — intervention group
Group type: COMPARATOR
Intervention: Unilateral tap water iontophoresis
Number of subjects: 20
Study 15527429 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral glycopyrrolate iontophoresis
Number of subjects: 20
Study 15527429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral glycopyrrolate iontophoresis
Number of subjects: 20
Study 11110999 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste (sip-and-spit energy-dense preload)
Number of subjects: 24
Study 11110999 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste/kcal (energy-dense preload)
Number of subjects: 24
Study 11110999 — intervention group
Group type: COMPARATOR
Intervention: Water (water preload)
Number of subjects: 24
Study 8936611 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Diabetics
Number of subjects: 121
Study 8936611 — intervention group
Group type: COMPARATOR
Intervention: Non-Diabetics (Young)
Number of subjects: 121
Study 8936611 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly Diabetics
Number of subjects: 121
Study 8936611 — intervention group
Group type: COMPARATOR
Intervention: Non-Diabetics (Elderly)
Number of subjects: 121
Study 1583252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 micrograms once daily
Number of subjects: 44
Study 1583252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 1583252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 44
Study 3990300 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 98
Study 3990300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 31076272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and locally administered corticosteroids
Number of subjects: 0
Study 31076272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroid spray and antihistamine drugs
Number of subjects: 0
Study 31076272 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training using odorants
Number of subjects: 0
Study 31076272 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory testing
Number of subjects: 0
Study 29321008 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quitline services plus Pathways to Freedom (PTF) intervention
Number of subjects: 1050
Study 29321008 — intervention group
Group type: COMPARATOR
Intervention: Quitline services plus a standard tobacco cessation DVD (attention control)
Number of subjects: 1050
Study 29321008 — intervention group
Group type: COMPARATOR
Intervention: Quitline services alone (usual care)
Number of subjects: 1050
Study 26956041 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session cognitive-behavioral enhanced intervention (n=147)
Number of subjects: 296
Study 26956041 — intervention group
Group type: COMPARATOR
Intervention: One-session didactic information-only minimal intervention (n=149)
Number of subjects: 296
Study 24837690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once a day for up to 21 days
Number of subjects: 803
Study 24837690 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day for up to 21 days
Number of subjects: 803
Study 24837690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 803
Study 24837690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 23009311 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea 5% with arginine and carnosine (Ureadin Rx Db, ISDIN)
Number of subjects: 40
Study 23009311 — intervention group
Group type: COMPARATOR
Intervention: Glycerol-based emollient cream (Dexeryl, Pierre Fabre)
Number of subjects: 40
Study 19901309 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical assistant referral arm
Number of subjects: 864
Study 19901309 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 864
Study 18090458 — intervention group
Group type: EXPERIMENTAL
Intervention: Stalevo 50 (LCE50; 50/12.5/200 mg)
Number of subjects: 28
Study 18090458 — intervention group
Group type: EXPERIMENTAL
Intervention: Stalevo 100 (LCE100; 100/25/200 mg)
Number of subjects: 28
Study 18090458 — intervention group
Group type: EXPERIMENTAL
Intervention: Stalevo 150 (LCE150; 150/37.5/200 mg)
Number of subjects: 28
Study 18090458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet 100 (LC100; 100/25 mg)
Number of subjects: 28
Study 18090458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18090458 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (LCE50, LCE100, LCE150, LC100)
Number of subjects: 28
Study 18090458 — intervention group
Group type: EXPERIMENTAL
Intervention: LCE100 and LCE150
Number of subjects: 28
Study 15096909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine (0.2, 0.4 and 0.8 mg)
Number of subjects: 13
Study 15096909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (5 and 15 mg)
Number of subjects: 13
Study 15096909 — intervention group
Group type: COMPARATOR
Intervention: Cyclazocine (0 mg pretreatment)
Number of subjects: 13
Study 15096909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (100 mg intranasal)
Number of subjects: 13
Study 12880053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag-click condition at 43, 58, or 73 dB
Number of subjects: 127
Study 12880053 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-click condition
Number of subjects: 127
Study 12880053 — intervention group
Group type: EXPERIMENTAL
Intervention: Interclick interval (ICI) varied from 0.3 to 10 ms
Number of subjects: 127
Study 12880053 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from three highly experienced observers
Number of subjects: 127